In:
Future Oncology, Future Medicine Ltd, Vol. 4, No. 6 ( 2008-12), p. 759-768
Kurzfassung:
Li–Fraumeni syndrome is a rare autosomal dominant cancer predisposition syndrome. The majority of families fulfilling definition of Li–Fraumeni syndrome demonstrate inherited abnormalities involving the p53 gene. Cells with dysfunctional p53 are predisposed to the development of cancer phenotype. Advexin ® (Introgen Therapeutics Inc., TX, USA) is an adenoviral-based experimental therapeutic that provides delivery of wild-type p53 to cancer cells and demonstrates anticancer activity following adequate expression of p53. Theoretically, correction of p53 function in cancer developing in patients with Li–Fraumeni syndrome through treatment with Advexin will provide anti-tumor activity. One patient with Li–Fraumeni syndrome has been reported to have responded to Advexin. This review will summarize background knowledge of Li–Fraumeni syndrome, mechanisms of Advexin and clinical response of cancer to Advexin with a focus on Li–Fraumeni syndrome.
Materialart:
Online-Ressource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/14796694.4.6.759
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2008
